Ensysce Biosciences
ENSC
15 hedge funds and large institutions have $261K invested in Ensysce Biosciences in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 7 closing their positions.
0.43% less ownership
Funds ownership: 13.84% → 13.41% (-0.43%)
12% less funds holding
Funds holding: 17 → 15 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
43% less capital invested
Capital invested by funds: $461K → $261K (-$200K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.8K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15.4K |
| 4 |
Jane Street
New York
|
+$8.61K |
| 5 |
VF
Virtu Financial
New York
|
+$8.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$90.6K |
| 2 |
FPI
Financial Plan Inc
Bellingham,
Washington
|
-$22.1K |
| 3 |
HF
HRT Financial
New York
|
-$22K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$19.9K |
| 5 |
WN
Williams & Novak
Westlake Village,
California
|
-$16.4K |
ENSC Hedge Fund Activity: Q1 2026 in Review
15 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q1 2026, worth a combined $261K — down 43% from $461K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ENSC and 6 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $36.4K. The largest seller was DRW Securities, exiting entirely with an estimated $90.6K sold.
- 15 institutional investors held Ensysce Biosciences (ENSC) as of Q1 2026, down from 17 in Q4 2025.
- Funds reported $261K of Ensysce Biosciences stock for Q1 2026, down 43% quarter-over-quarter.
- 6 funds opened new Ensysce Biosciences positions in Q1 2026 and 7 closed out, a net change of -1 holder.
- The largest Ensysce Biosciences buyer in Q1 2026 was Citadel Advisors, an estimated $36.4K added.
- The largest Ensysce Biosciences seller in Q1 2026 was DRW Securities, an estimated $90.6K sold.
Based on aggregated 13F filings for Q1 2026.